European Marketing Authorization Holder (MAH)

Your Trusted MAH Partner in Europe

A Marketing Authorization Holder (MAH) is the legal entity responsible for obtaining and maintaining the authorization to market a medicinal product across Europe. The MAH ensures compliance with EU/UK regulations, including Good Manufacturing Practices (GMP), pharmacovigilance obligations, medical information governance, supply chain oversight, and quality control. The responsibility for the performance of a medicinal product over its lifetime, its safety, quality and efficacy, lies with the MAH. For pharmaceutical companies without an EU or UK presence, securing an experienced MAH partner is critical to regulatory success and sustainable market access.

Speak with an Expert

Why Choose ProPharma?

With over 20 years of experience in commercializing medicinal products, ProPharma has successfully supported pharmaceutical companies worldwide in achieving marketing authorization, achieving reimbursement, and maintaining compliance. We provide:

A trusted partner for all MAH responsibilities, including acting as your MAH
Expert guidance tailored to your specific regulatory, market access, and medical information needs
Comprehensive support from regulatory submissions to post-market compliance
Proven success in navigating country-specific pricing and reimbursement challenges
EU and UK MIA licenses and WDA support>
Fully outsourced contact centre services, with over 35 languages supported

Partner with ProPharma to simplify your market entry across Europe and ensure long-term compliance. Contact us today to learn more about how we can support your marketing authorization and post-approval needs.

Speak with an Expert

professionals-pointing-to-laptop-as-914178358

ProPharma's Comprehensive MAH Services

Navigating both the specific country and centralized European regulations and requirements to supply medicinal products to the European markets can be a complex challenge.

With decades of experience, our experts provide a full spectrum of MAH services to support pharmaceutical companies in successfully navigating the regulatory requirements across Europe. Our tailored solutions ensure compliance, streamline market entry, maintain product integrity, and support patient access.

Regulatory & Compliance Support

Guidance on selecting the optimal regulatory pathway
Full gap analysis, MAA readiness assessment and pre-submission activity support
End-to-end regulatory submissions for marketing authorization applications (Centralized, Decentralized, Mutual Recognition, and National Procedures)
Maintenance of marketing authorizations, including variations and renewals
Dossier preparation and procedural management
Lifecycle management

Pharmacovigilance & Safety Management

PV gap analysis to ensure inspection readiness
Full pharmacovigilance system implementation, including QPPV services
Development and maintenance of the Pharmacovigilance System Master File (PSMF)
Signal detection, case processing and submission, literature search, and risk management planning
Compliance with Good Pharmacovigilance Practices (GVP) requirements
Provision of Local responsible Person for Pharmacovigilance (LPPV), as applicable

Quality & Manufacturing Oversight

EEA/UK GMP compliance support, including Qualified Person (QP) and Responsible Person (RP) services
Batch release and supply chain oversight for seamless product distribution
Manufacturing license (MIA) support and QP declarations
Labelling, packaging, and serialization compliance with EEA/UK standards

Market Access & Commercialization

Strategic support for pricing and reimbursement
Joint Clinical Assessment (JCA) dossier preparation and submission
National Health Technology Assessment (HTA) dossier preparations and submissions
Guidance on selecting the optimal market entry
Competitive landscape analysis and product positioning
Price and reimbursement maintenance, including renewals

Contact Centre Support in 35+ Languages

Front desk services – central point for inquiries in 35+ languages, including adverse event reporting
Support for Named Patient Supply (NPS) programs
Written medical responses, aligned with the SmPC, safety data, and regulatory requirements
Triage and escalate safety information in collaboration with pharmacovigilance teams
Scalable models to support launch, post-approval, and lifecycle management
Medical communication supporting patient access and ongoing product use

Tailored Solutions for Specific Challenges

Pharmaceutical companies—whether generic or biosimilar manufacturers, orphan drug or ATMP (cell and gene) manufacturers, non-EU companies or innovative drug developers—face unique challenges in obtaining EU marketing authorization. Beyond regulatory approval, companies must also manage post-authorization obligations such as pharmacovigilance, medical information, compliance, and patient access. ProPharma offers specialized, integrated solutions to address these hurdles across the entire product lifecycle.

Challenges Faced by Non-European Companies & ProPharma Solutions

ProPharma offers comprehensive support by guiding companies through regulatory pathways, conducting gap analyses, facilitating regulatory meetings, ensuring quality compliance, and providing QPPV services. With expertise in pricing strategies and logistics, ProPharma streamlines the EU market entry process for US companies, ensuring regulatory success and commercial viability.

Challenge: Understanding EMA requirements vs. FDA and/or other regional regulations.
Solution:ProPharma provides expert guidance on EEA/UK regulatory frameworks.

Challenge: Adapting US-based clinical data to meet EEA/UK standards.
Solution: ProPharma conducts gap analyses and supports data generation.

Challenge: Engaging effectively with EMA and national authorities.
Solution: ProPharma facilitates pre-submission meetings and regulatory discussions.

Challenge: Aligning with EEA/UK GMP, GDP, and GVP requirements.
Solution: ProPharma assists in quality system implementation and compliance.

Challenge: Setting up a compliant EEA/UK pharmacovigilance system in more than 30 countries.
Solution: ProPharma offers full pharmacovigilance services, including QPPV and LPPV appointment tailored to our clients needs.

Challenge: Navigating European JCA requirements and complex country-specific HTA and reimbursement processes.
Solution: ProPharma prepares JCA dossier for submission on a European level and develops country-specific pricing and reimbursement dossiers for submission.

Challenge: Establishing an efficient and compliant supply chain.
Solution: ProPharma provides MIA and QP declaration support.

Challenge: Meeting EMA expectations that medical information (MI) must be accessible across 24 official EU languages.
Solution: ProPharma delivers scalable, multilingual MI through contact centres, ensuring accurate, compliant responses in every required EU language.

Challenge: Coordinating consistent, high-quality medical information across multiple countries and languages — particularly for companies with limited internal resources.
Solution: ProPharma centralises and streamlines multilingual operations that maintains quality, consistency, and regulatory compliance across all EU markets.

Challenge: Balancing rapid, local-language responses with strict regulatory and PV requirements.
Solution: ProPharma combines regulatory expertise with trained, native-language medical information professionals to ensure every inquiry is handled accurately, compliantly, and in alignment with EMA expectations.

Challenges Faced by Generic or Biosimilar Development Companies & ProPharma Solutions

ProPharma provides tailored solutions by offering expert guidance on bioequivalence studies, dossier compliance, and regulatory submissions, as well as comprehensive support for GMP implementation, QPPV services, and pricing strategies. By streamlining the authorization process, ProPharma enables generic and biosimilar development companies to efficiently enter and succeed in the European market.

Challenge: Proving bioequivalence to the Reference Medicinal Product (RMP) requires well-designed studies and robust data analysis.
Solution: ProPharma advises on study design, conducts rigorous data analysis, and ensures EMA compliance for successful bioequivalence demonstration.

Challenge: Selecting the optimal approval pathway can be complex.
Solution: ProPharma provides strategic guidance and application management centralized and across multiple EU member states.

Challenge: Adapting existing data to meet EU regulatory standards.
Solution: ProPharma ensures dossier compliance, including API characterization and stability studies.

Challenge: Variations or withdrawals of the RMP affecting generic approvals.
Solution: ProPharma actively monitors RMP changes and advises on regulatory updates.

Challenge: Ensuring compliance with EEA/UK GMP standards.
Solution: ProPharma supports GMP implementation and quality assurance.

Challenge: Maintaining a compliant pharmacovigilance system.
Solution: ProPharma offers full pharmacovigilance support, including QPPV services and risk management.

Challenge: Navigating country-specific aggressive generic drug price controls and pricing regulations.
Solution: ProPharma provides full competitive pricing analysis followed by reimbursement preparation and submission with price maintenance support.

News & Insights

Thought Leadership Webinars Press Awards Resource Library

June 15, 2026

Five Metrics That Predict CRO Success (and How to Measure Them)

Discover five key metrics to evaluate CRO success, ensuring timely clinical trials and data integrity while minimizing costs. Learn how to measure them effectively.

Read Full Article

June 10, 2026

FDA Adds Bemotrizinol to OTC Sunscreen Monograph: What the New GRASE Determinati...

Learn how bemotrizinol achieved GRASE status and what FDA's final order adding the ingredient to the OTC sunscreen monograph means for manufacturers and product development.

Read Full Article

June 8, 2026

Modernizing Case Management for Global Compliance

Discover how E2B (R3) is modernizing pharmacovigilance case management, improving compliance, and streamlining adverse event reporting across global regulatory authorities.

Read Full Article

View all Thought Leadership

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

Read Full Article

May 27, 2026

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.

Read Full Article

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

Read Full Article

View all Press

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

Read Full Article

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

Read Full Article

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Read Full Article

View all Awards

Case Study

June 17, 2026

Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...

Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...

Read Full Article

Case Study

June 10, 2026

Accelerating Commercial Readiness for a Novel Cell Therapy Program

As advanced therapy developers move from research-stage operations toward commercialization, they often face significant challenges in scaling quality systems, aligning regulatory strategy, and...

Read Full Article

Case Study

May 20, 2026

Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed

When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...

Read Full Article

View all Resources

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Watch the Replay

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

Watch the Replay

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

Watch the Replay

View all Webinars

News & Insights

June 15, 2026

Five Metrics That Predict CRO Success (and How to Measure Them)

Discover five key metrics to evaluate CRO success, ensuring timely clinical trials and data integrity while minimizing costs. Learn how to measure them effectively.

Read This Article

June 10, 2026

FDA Adds Bemotrizinol to OTC Sunscreen Monograph: What the New GRASE Determinati...

Learn how bemotrizinol achieved GRASE status and what FDA's final order adding the ingredient to the OTC sunscreen monograph means for manufacturers and product development.

Read This Article

June 8, 2026

Modernizing Case Management for Global Compliance

Discover how E2B (R3) is modernizing pharmacovigilance case management, improving compliance, and streamlining adverse event reporting across global regulatory authorities.

Read This Article

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

Read This Article

May 27, 2026

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.

Read This Article

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

Read This Article

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

Read This Article

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

Read This Article

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Read This Article

Case Study

June 17, 2026

Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...

Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...

View This Resource

Case Study

June 10, 2026

Accelerating Commercial Readiness for a Novel Cell Therapy Program

As advanced therapy developers move from research-stage operations toward commercialization, they often face significant challenges in scaling quality systems, aligning regulatory strategy, and...

View This Resource

Case Study

May 20, 2026

Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed

When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...

View This Resource

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Watch the Replay

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

Watch the Replay

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

Watch the Replay